This study is in progress, not accepting new patients
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Summary
- Eligibility
- for people ages 18-120 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- Links
- Merck Oncology Clinical Trials Information Plain Language Summary
- ID
- NCT04626479
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 400 study participants
- Last Updated